European Journal of Clinical Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

High intra-patient variability of tacrolimus within post-operative 1  month predicted worse 1-year outcomes in pediatric liver transplant recipients
ConclusionsPLT recipients with high TAC trough concentration of CV in the first month were associated with poor 1-year outcomes. This CV calculation provides a valuable strategy to monitor TAC exposure. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 19, 2024 Category: Drugs & Pharmacology Source Type: research

Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients
ConclusionPatients with HFpEF experienced benefits from SGLT2i administration, as evidenced by improved 6-min walk distances and weight reduction. Dapagliflozin demonstrated clinical and overall improvements in KCCQ scores and was more effective in reducing weight than the placebo. Both Dapagliflozin and Empagliflozin were well-tolerated and exhibited favorable safety profiles. Future studies could benefit from a larger patient population, a longer follow-up period, and a broader range of SGLT2i. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review
ConclusionA more rigorous external evaluation needs to be performed before routine clinical use to select the appropriate PopPK model. Further research is necessary to incorporate larger cohorts or pool analyses in specific susceptible pediatric populations to improve the understanding of predicted exposure profiles and covariate identification. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 18, 2024 Category: Drugs & Pharmacology Source Type: research

Tyrosine kinase inhibitor –induced hypothyroidism: mechanism and clinical implications
DiscussionThis review discusses the epidemiology, possible mechanisms, and clinical significance of hypothyroidism in cancer patients treated with TKI. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics of polymyxin B in different populations: a systematic review
ConclusionWe conclude  that small sample sizes, lack of multicentre collaboration, and patient homogeneity are the primary reasons for the discrepancies in the results of the current studies. In addition, most of the studies limited in the internal evaluation, which confined the implementation of model-informed precis ion dosing strategies. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Source Type: research

ChatGPT for generating multiple-choice questions: a reply
(Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 14, 2024 Category: Drugs & Pharmacology Source Type: research

Retraction Note: Graphical representation of network meta-analysis: an iconographic support to the complexity of multiple data comparisons
(Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line
ConclusionConcomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Source Type: research

Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany
ConclusionIn a real-world setting, despite higher age than in clinical trials, adherence and persistence of vericiguat appeared satisfactory across age categories. Initiation of vericiguat was associated with intensification of concomitant GDMT. Nevertheless, barriers to vericiguat up-titration and implementation of other GDMT, applying in particular to women and elderly patients, need to be investigated further. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Source Type: research

Activities of clinical pharmacologists across Europe: A survey by the European association of clinical pharmacology and therapeutics
ConclusionCPT comes with a plurality of backgrounds and activities, all required to embrace the different pathologies and the whole lifecycle of medicinal products, but all of them being rarely performed in any given country. The willingness to use common CPT teaching material and prescribing exams at the European level is a good sign of increasing harmonisation of our discipline Europewide. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Source Type: research

Incidence, characteristics, and risk factors of drug-associated muscle adverse reaction: a retrospective real-world study of inpatients
ConclusionHealthcare professionals should be vigilant with patients exhibiting the identified risk factors. Monitoring creatine kinase and related indices when using myotoxic drugs is crucial to preventing serious adverse reactions, ultimately preserving patients ’ quality of life. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Source Type: research